Patent Extension Review Finalized for TECELRA Medicine
Published Date: 7/14/2025
Notice
Summary
The FDA has officially set the review period for TECELRA, a medicine that helps people, so its patent can be extended. This means the company behind TECELRA can get extra time to protect their invention and keep making money before others can copy it. If you’re involved in drug patents or medicine development, this timing update is a big deal!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Patent Extension Eligibility for TECELRA
The FDA has determined the regulatory review period for TECELRA so the company can apply to the U.S. Patent and Trademark Office for a patent extension. If you work for or own the company that makes TECELRA, this lets the company seek extra time to protect the medicine and keep making money before others can copy it.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in